Retatrutide Research: Triple GLP-1/GIP/Glucagon Signaling
Retatrutide takes the incretin-agonist idea a step further than dual agonists: it engages three receptors — GLP-1, GIP, and the glucagon receptor. Adding glucagon-receptor activity is the conceptual leap, because glucagon signaling is associated with energy expenditure. As with other incretin compounds, human research exists; this summary reports it for educational reference, and the material here is supplied strictly for laboratory Research Use Only.
A triple-hormone-receptor agonist
The compound was introduced in pharmacology research as a novel GLP-1, GIP, and glucagon receptor agonist studied for metabolic endpoints (Coskun et al., Cell Metab, 2022). [1] The glucagon arm is what distinguishes it from dual agonists like tirzepatide.
Early clinical research
A phase-2 trial studied retatrutide for body-weight outcomes in an obesity-research population (Jastreboff et al., N Engl J Med, 2023). [2] It sits within a broader pipeline of next-generation metabolic compounds that reviews have begun to map (Melson et al., Int J Obes, 2024). [3]
Primary literature & related
- 1. Coskun et al. — LY3437943, triple GLP-1/GIP/glucagon agonist (Cell Metab, 2022)
- 2. Jastreboff et al. — retatrutide phase-2 obesity trial (NEJM, 2023)
- 3. Melson et al. — pipeline of future obesity medications (Int J Obes, 2024)
- Retatrutide product page (full cited research)
- Tirzepatide profile (dual-receptor agonist)
Frequently Asked Questions
How is retatrutide different from tirzepatide?
Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds a third target, the glucagon receptor, making it a triple-receptor agonist in the research literature.
